ORIC Pharmaceuticals, Inc. announced its clinical development plans for its lead programs, ORIC-944 and ORIC-114, while reporting financial results for the first quarter of 2025. The company presented ...
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as ...
Good morning, and welcome to the NovaBridge Biosciences Business Update Call. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be made available on the NovaBridge ...
Laboratory assessments — from preclinical research through post-marketing surveillance — determine whether a cell-based therapy for cancer succeeds or fails. “Every developer out there advancing CAR T ...
- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX) (Nasdaq: CGTX), a clinical-stage company developing product ...
Boundless Bio has announced it will not advance BBI-825 into the second part of the STARMAP clinical trial due to challenges related to emerging clinical data and the competitive landscape for ...
- Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results